Focus on Crohn's disease

被引:0
|
作者
Klotz, Caroline [1 ]
Dhooge, Marion [1 ,2 ]
Oudjit, Ammar [3 ]
Barret, Maximilien [1 ,2 ]
Beuvon, Frederic [4 ]
Chaussade, Stanislas [1 ,2 ]
Coriat, Romain [1 ,2 ]
Abitbol, Vered [1 ]
机构
[1] Hop Cochin, AP HP, Serv Gastroenterol, F-75674 Paris, France
[2] Univ Paris 05, Fac Med, F-75014 Paris, France
[3] Hop Cochin, AP HP, Serv Radiol, F-75014 Paris, France
[4] Hop Cochin, AP HP, Serv Anatomopathol, F-75014 Paris, France
来源
PRESSE MEDICALE | 2015年 / 44卷 / 04期
关键词
CLINICAL-RESPONSE; INFLIXIMAB; THERAPY; MAINTENANCE; AZATHIOPRINE; ADALIMUMAB; BIOMARKERS; REMISSION; EFFICACY; ANTIBODY;
D O I
10.1016/j.lpm.2014.07.028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Crohn's disease is an inflammatory bowel disease that affects the entire digestive tract, from the mouth to the anus. The inflammatory disease is transmural and may be complicated by abscesses, fistulas, strictures. Budesonide is used as first-line treatment for a first episode of ileitis. Thiopurines and methotrexate are used as immunosuppressive maintenance therapy. Anti-tumour necrosis factors (TNF) alpha therapy is used as induction and maintenance therapy in case of severe flares or corticodependence. Combination of immunosuppressive therapy and anti-TNF-alpha (combotherapy) prevents the appearance of specific anti drug antibodies. Combotherapy is used in case of severe disease. The goal of the treatment is to achieve clinical remission, endoscopic mucosal healing, and to prevent the occurrence of complications such as strictures, fistulas or abscesses. Anoperineal lesions are found in 10% of the patients at diagnosis. Surgical treatment is indicated for severe medical treatment-resistant patients or complications such as symptomatic stenosis, fistula or abscess unresponsive to medical treatment or immediately complicated.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 50 条
  • [31] Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study
    Vande Casteele, Niels
    Baert, Filip
    Bian, Sumin
    Dreesen, Erwin
    Compernolle, Griet
    Van Assche, Gert
    Ferrante, Marc
    Vermeire, Severine
    Gils, Ann
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (10) : 1248 - 1256
  • [32] Crohn's disease and hyperbaric oxygen therapy
    Iezzi, Leonardo Estenio
    Feitosa, Marley Ribeiro
    Medeiros, Bruno Amaral
    Aquino, Jussara C.
    Normanha Ribeiro de Almeida, Ana Luiza
    Parra, Rogerio Serafim
    Ribeiro da Rocha, Jose Joaquim
    Feres, Omar
    ACTA CIRURGICA BRASILEIRA, 2011, 26 : 129 - 132
  • [33] Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
    Watanabe, Mamoru
    Hibi, Toshifumi
    Lomax, Kathleen G.
    Paulson, Susan K.
    Chao, Jingdong
    Alam, M. Shamsul
    Camez, Anne
    JOURNAL OF CROHNS & COLITIS, 2012, 6 (02) : 160 - 173
  • [34] Evolving Definitions of Remission in Crohn's Disease
    Panaccione, Remo
    Colombel, Jean-Frederic
    Louis, Edouard
    Peyrin-Biroulet, Laurent
    Sandborn, William J.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (08) : 1645 - 1653
  • [35] Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn's Disease: A Case Series
    Fujiwara, Kaori
    Inoue, Takuya
    Yorifuji, Naoki
    Iguchi, Munetaka
    Sakanaka, Taisuke
    Narabayashi, Ken
    Kakimoto, Kazuki
    Nouda, Sadaharu
    Okada, Toshihiko
    Abe, Yosuke
    Takeuchi, Toshihisa
    Higuchi, Kazuhide
    INTERNAL MEDICINE, 2015, 54 (20) : 2603 - 2607
  • [36] Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary
    Kosa, Fruzsina
    Kunovszki, Peter
    Borsi, Andras
    Ilias, Akos
    Palatka, Karoly
    Szamosi, Tamas
    Vincze, Aron
    Molnar, Tamas
    Lakatos, Peter L.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (03) : 274 - 280
  • [37] Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease
    Singh, Siddharth
    Heien, Herbert C.
    Sangaralingham, Lindsey R.
    Schilz, Stephanie R.
    Kappelman, Michael D.
    Shah, Nilay D.
    Loftus, Edward V., Jr.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (08) : 1120 - +
  • [38] Differences in the need for adalimumab dose optimization between Crohn's disease and ulcerative colitis
    Olivares, David
    Alba, Cristina
    Perez, Irene
    Roales, Valentin
    Rey, Enrique
    Taxonera, Carlos
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (11) : 846 - 851
  • [39] Adalimumab for Crohn's Disease in Clinical Practice at Mayo Clinic: The First 118 Patients
    Swoger, Jason M.
    Loftus, Edward V., Jr.
    Tremaine, William J.
    Faubion, William A.
    Pardi, Darrell S.
    Kane, Sunanda V.
    Hanson, Karen A.
    Harmsen, W. Scott
    Zinsmeister, Alan R.
    Sandborn, William J.
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (11) : 1912 - 1921
  • [40] Severe and steroid-resistant Crohn's disease
    Michetti, Pierre
    Mottet, Christian
    Juillerat, Pascal
    Pittet, Valerie
    Felley, Christian
    Vader, John-Paul
    Gonvers, Jean-Jacques
    Froehlich, Florian
    DIGESTION, 2007, 76 (02) : 99 - 108